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Africa, Asia, and Latin America are regions highly affected by endemic diseases, such
as Leishmaniasis, Malaria, and Chagas’ disease. They are responsible for the death
of 1000s of patients every year, as there is not yet a cure for them and the drugs
used are inefficient against the pathogenic parasites. During the life cycle of some
parasitic protozoa, insects become the most important host and disseminator of the
diseases triggered by these microorganisms. As infected insects do not develop nocive
symptoms, they can carry the parasites for long time inside their body, enabling their
multiplication and life cycle completion. Eventually, parasites infect human beings after
insect’s transmission through their saliva and/or feces. Hence, host insects and general
arthropods, which developed a way to coexist with such parasites, are a promising
source for the prospection of anti-parasitic compounds, as alternative methods for
the treatment of protozoa-related diseases. Among the molecules already isolated and
investigated, there are proteins and peptides with high activity against parasites, able
to inhibit parasite activity in different stages of development. Although, studies are still
taking their first steps, initial results show new perspectives on the treatment of parasitic
diseases. Therefore, in this report, we describe about peptides from host insect sources
with activity against the three most endemic parasites: Leishmania sp., Plasmodium
sp., and Trypanosomes. Moreover, we discuss the future application insect peptides as
anti-parasitic drugs and the use of non-hosts insect transcriptomes on the prospection
of novel molecules for the treatment of parasitic neglected diseases.
Keywords: proteins, peptides, anti-parasitic, host insects, tropical diseases
INTRODUCTION
In 1970, the Rockefeller Foundation introduced the term “the Great Neglected Diseases,”
corresponding to several illnesses caused by infectious microorganisms and parasites (viruses,
bacteria, fungi, protozoa, and helminthes), endemic in poor populations of Asia, Africa, and
America. Neglected diseases received this name due to the lack of interest by health science
researchers and pharmaceutical companies on developing and commercializing products for their
treatment or cure. Consequently, studies on this ﬁeld are poorly invested (Souza, 2010).
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However, during the last 20 years, the pattern of neglected
diseases worldwide has changed, asmortality rates are decreasing,
while morbidity still grows on the population. All neglected
diseases are closely related to poverty, lack of hygiene, food
and quality of life. Therefore, it is diﬃcult to include long-time
treatment programs, as most of the patients have no ﬁnancial
conditions to pay for the drugs (Paes and Silva, 1999; Brasil,
2010).
Chagas diseases, Leishmaniasis, and Malaria are some of these
neglected diseases. Chagas disease, ﬁrst reported in America
during 1909, was classiﬁed as an enzootic illness aﬀecting mostly
the poor population of Latin America. Nevertheless, nowadays,
it became a worldwide concern, as it spread through many
countries in Africa, Europe, and Asia (Coura and Viñas, 2010;
World Health Organization [WHO], 2014, 2015a). Migration
processes of contaminated people to non-endemic regions and
environmental changes in forestry areas, favoring trypanosome
parasites to adapt into domestic environment, increased the
identiﬁcation of Chagas disease cases in North America, Western
Paciﬁc region and at least 16 countries of Europe. Therefore, new
forms of parasite transmission were described, including blood
transfusion, organ transplantation, and vertical transmission
from mother to child (Coura and Viñas, 2010; World Health
Organization [WHO], 2014). The constant migration of people
from diﬀerent countries during the last two decades enlarged
epidemiological and social matters, leading to an evaluation of
economic and political aspects for the prevention, treatment, and
eradication of this disease (World Health Organization [WHO],
2015a).
Leishmaniasis is another neglected disease with high concern
to many countries worldwide. In February, the World Health
Organization [WHO] (2015b) estimated 1.3 million new cases
of Leishmaniasis (visceral and cutaneous) and 20,000–30,000
deaths annually. The cutaneous form of Leishmaniasis occurs
in diﬀerent populations of the world, although higher rates are
observed in South American and African countries. On the other
hand, 90% of all cases of visceral Leishmaniasis is concentrated
in Bangladesh, Brazil, Ethiopia, India, Sudan, and South Sudan
(Alvar et al., 2012). In Brazil, Leishmaniasis is showing an
expansion, generally associated with environmental modiﬁcation
caused by man, population displacements arising from endemic
areas and insuﬃcient infrastructure in water and sewer systems
(Paes and Silva, 1999; Brasil, 2010).
Additionally, Malaria is one of the most important parasitic
infectious disease of the world. It occurs in tropical and
subtropical areas of 106 countries worldwide. Only in 2012,
627,000 1000 people in the SaharanAfrica died ofMalaria (Center
for Disease Control and Prevention [CDC], 2014). Although an
estimative from the World Malaria Report consider a signiﬁcant
decrease in the number of countries exposed toMalaria (from 140
to 106), every year, 100s of millions of new episodes are registered
in diﬀerent regions of the world (Public Health England, 2014;
World Malaria Report, 2015).
Most of neglected diseases have low ﬁnancial support, both
from Private and Governmental funds. However, great amount of
international funding is given to control new cases of Malaria in
endemic countries, as well as applied on preventive Programs for
poor populations. The amount invested on the control of Malaria
worldwide raised from US$ 960 million in 2005 to US$ 2.5 billion
in 2014 (World Malaria Report, 2015). The number increased 8%
between 2013 and 2014, but the ﬁnancial support invested on
the prevention and treatment of Malaria are still not suﬃcient
to contain the arrival of new cases.
Hence, part of the ﬁnancial investments applied on Malaria,
Leishmaniasis, and Chagas’ disease is spent on research for
the discovery of novel molecules that can be used as new
pharmaceutical products for the treatment of these illnesses.
Recently, studies demonstrated that the use of peptides isolated
from host mosquitoes and other invertebrates, called anti-
parasitic peptides (APPs), are the key to inhibit or even kill
protozoa cells infecting the human body (Li et al., 2006; Moreira
et al., 2007; Tian et al., 2008; Fieck et al., 2010; Gao et al., 2010;
Rangel et al., 2011; Marr et al., 2012).
Therefore, this report describes the ﬁrst studies related to
the activity of diﬀerent peptides from insect hosts APPs against
three parasite species: Trypanosoma sp., Leishmania sp., and
Plasmodium sp. The results reported here show the great
potential of using insect host proteins and peptides to treat
Chagas disease, Leishmaniasis, and Malaria in human patients.
NEW STRATEGIES FOR THE
TREATMENT OF CHAGAS DISEASE
Chagas disease is a human trypanosomiasis endemic in Latin
America countries, caused by the species Trypanosoma cruzi.
The name was given by the scientist Carlos Chagas, in honor of
the research developed by Oswaldo Cruz, during the beginning
of the 20th century. The transmission occurs when a person is
bitten by a triatomine insect containing T. cruzi parasites (Don
and Chatelain, 2008). Common triatomines of Chagas disease
vectors belong to Triatoma, Rhodnius, and Panstrongylus generi.
In Central and South America, the most common triatomine is
T. prolixus (Fieck et al., 2010).
Chagas’ disease can be classiﬁed into three diﬀerent stages:
acute, asymptomatic, and chronic. The acute stage consists
of fever, facial edema, generalized lymphadenopathy, and
hepatosplenomegaly. Usually, 5% of contaminated children die
during this stage, but the illness can spontaneously undertake
itself in 4–6 weeks, becoming asymptomatic. During this stage,
also called indeterminate, the parasite passes to its second phase,
which can last from 10 years to a lifetime. The last and most
concerning stage is the chronic phase, once the disease can
compromise the heart, leading to death by cardiac arrhythmia
or congestive heart failure (Whitebread et al., 2005; Don and
Chatelain, 2008). Therefore, Chagas disease has become one of
the main causes of heart problems in Latin America countries,
as well as gastrointestinal mega-syndromes in some patients
(Chagas, 1981; Parada et al., 1997).
It is estimated that 11 million people in American countries
are infected with T. cruzi, and 10–30% of them will develop the
chronic stage of Chagas disease (Bern et al., 2007). There is no
cure for Chagas disease and the available treatments correspond
to the use of benznidazole or nifurtimox. Both are eﬀective
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only in 50% of the cases, and for patients in the acute or early
indeterminate stages. There is still no treatment, nor even a cure,
for the late indeterminate and chronic stages of Chagas disease
(Kennedy, 1997; Whitebread et al., 2005; Frearson et al., 2007).
Until now, there are also no vaccines developed to prevent
infection by T. cruzi, neither eﬀective vector eradication
Programs to control parasite dissemination (Kevin, 2014).
Thus, there is a strong need for the development of adequate
therapeutic strategies to treat Chagas disease. Preliminary work
described the use of peptides capable of lysing diﬀerent cell types
(Kehoe and Timmis, 1984). Therefore, the utilization of proteins
and peptides from diﬀerent sources became a strategic alternative
for the control of parasites.
Another interesting feature is the inability of parasites to
damage the cells of their insect hosts. Although, the infection
with the parasite can cause several damages in human organs, it
is harmless to triatomine insects (Rosendaal, 1997). In this way,
investigating proteins and peptides from parasite’s insect hosts is
a prospering alternative for the development of new tools against
Chagas disease.
Anti-trypanosomal Peptides
There are still, in literature, very few studies on the prospection
and evaluation of the anti-trypanosomal eﬀect of proteins and
peptides from insect sources, especially for species causing
Chagas disease. Among all classes of proteic molecules, only three
have been studied for this purpose: apidaecins, cecropins, and
melittins (Table 1).
Apidaecins correspond to a group of small prolin-rich
peptides, ranging from 18 to 20 amino acid residues, previously
isolated from the honeybees Apis melifera (Casteels et al., 1989;
Li et al., 2006). They have been widely studied as potential
molecules for therapeutic use due to their anti-bacterial activity
and harmless impact against human and animal cells (Casteels
and Tempst, 1994; Li et al., 2006). Recent studies showed that
this class of peptides can also present anti-trypanocidal activity at
an absolute lethal concentration (LC100) of 199 μM (Fieck et al.,
2010).Moreover, when used in pairwise treatments, together with
magainin II (from the Xenopus laevis), cecropin (from the silk
worm) and melittin (also from honeybee), the anti-trypanocidal
activity increased 10 folds, showing additive eﬀects at a half
maximal inhibitory concentration (IC50) of 0.70μM (Fieck et al.,
2010).
Cecropins include a class of small and basic peptides of about
31–37 amino acid residues. They were ﬁrst isolated from the
silk moth Hyalophora cecropia, and have been described as an
important molecule in the cell-free immunity of insects, with
activity against bacteria and fungi growth (Boman, 1991; Boman
et al., 1991). Earlier studies demonstrated the performance of
synthetic cecropins against T. cruzi.The synthetic peptides, called
SB-37 and Shiva-1, with punctual mutations in their amino acid
sequence, were able to kill trypomastigote forms of the parasite
after 1-h exposure, in a dose-responsive manner (Jaynes et al.,
1988). Interestingly, Shiva-1 peptide was 10 times more eﬀective
against Trypomastigotes than SB-37, in terms of parasite damage
and lysis.
TABLE 1 | Insect peptides with anti-parasitic activity.
Anti-parasitic
activity
Peptide Insect species Targeted
parasite(s)
Half maximal inhibitory
concentration (IC50)
Mortality rate Reference
Anti-tripanosomal Cecropin Hyalophora cecropia Trypanosoma cruzi 0.8 μM NI Fieck et al., 2010
Melittin Apis melífera venom T. cruzi 0.8 μM NI Fieck et al., 2010
Meucine-24 A. melífera venom T. cruzi 10–20 μM NI Gao et al., 2010
Anti-malarial Cecropin B H. cecropia Plasmodium sp. 0.5 μg/μl (128 μM) Gwadz et al., 1989
Cecropin A H. cecropia P. falciparum >100 μM NI Boman et al., 1989
Drosomycin 1 Drosophila
melanogaster
P. berghei NI 76% mortality
at 20 μM
Tian et al., 2008
Drosomycin 2 D. melanogaster P. berghei NI 29% mortality
at 20 μM
Tian et al., 2008
Gambicin Anopheles sp. P. berghei 10 μM NI Vizioli et al., 2001
Gomesin A. gomesi P. falciparum, P.
berghei
75.8–86.6 μM NI Moreira et al., 2007
Meucine-25 Mesobuthus eupeus P. berghei 10–20 μM NI Gao et al., 2010
Scorpine Pandinus imperator P. berghei NI 98% mortality
at 15 μM
Carballar-Lejarazu et al.,
2008
P. falciparum NI 100% mortality
at 5 μM
Carballar-Lejarazu et al.,
2008
Anti-leishmanial Decoralin Oreumenes decoratus L. major 72 μM NI Konno et al., 2007
Decoralin-NH2 Derived from Decoralin L. major 11 μM NI Konno et al., 2007
Eumenitin Eumenesru
rubronotatus
Leishmania sp. 35 μM NI Rangel et al., 2011
Spinigerin P. messpiniger L. donovani 150 μM NI Landon et al., 2006
Tachyplesin Tachypleus tridentatus L. braziliensis 12.5 μM NI Löfgren et al., 2008
NI, not indicated by the authors.
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Another report showed that a Cecropin A displayed
trypanostatic eﬀects against Chagas diseases parasite, inhibiting
its growth at a LC100 of 80 μM, although it was not able to
kill T. Cruzi cells (Fieck et al., 2010). However, when coupled
with other peptides, such as magainin, an antagonistic eﬀect was
observed, at a concentration of 0.1 and 1.0 μM for cecropin and
magainin, respectively (Fieck et al., 2010).
Furthermore, melittin is a small 26-amino acid peptide
isolated from honeybee venom with anti-microbial activity
against yeasts and bacteria (Lubke and Garon, 1997; Klotz
et al., 2004; Lazarev et al., 2005). It also has showed ability to
inhibit protein kinase C, protein kinase II, and myosin kinase
(Yang and Carrasquer, 1997). Previous reports described the
potential use of melittin on the treatment of epilepsy, HIV
infection, and cancer (Loftus, 2009; Hood et al., 2013; Verma
et al., 2013). Further studies demonstrated that melittin present
inhibitory activity against trypomastigotes (LD100 = 30 μM).
Also, when coupled with apidaecin, the parasite inhibitory
activity was increased. Nevertheless, when melittin was coupled
with cecropin, it showed an antagonistic eﬀect, contrary to
the additive eﬀect demonstrated with apidaecin (Fieck et al.,
2010).
Leishmania sp.: A MAMMALIAN
PARASITE TO BE DEFEATED
Leishmania is a genus of protozoa transmitted between mammals
by blood-sucking sandﬂies. Mammal species, including dogs,
mice and humans, are natural hosts for Leishmania and in
some parts of the world, like India, humans are the main hosts
(Kaye and Scott, 2011). The parasite’s live cycle encompasses
a diﬀerentiation of procyclic promastigote form into infective
metacyclic promastigote. This stage occurs inside sandﬂies, where
the parasite will be ready for transmission at the stomodea valve’s
insect. During blood-sucking, contaminated sandﬂies can inject
metacyclic promastigotes into mammal tissues together with
some parasite immunomodulatory elements. After phagocytized
by host cells, parasites will accommodate inside human body.
Then metacyclic promastigotes can become ﬂagellate amastigote
and replicates into host cells driving them to rupture, spreading
amastigotes into host tissues and allowing infection of others
phagocytes. The cycle is completed when infected phagocytes are
sucked by another sand-ﬂy and are converted in promastigotes
into sand-ﬂy’s midgut, re-starting a new cycle (Kaye and Scott,
2011).
There are more than 20 species of Leishmania related to
several subtypes of chronic skin and viscera infections, classiﬁed
as mucocutaneous disease, visceral disease, Leishmaniasis
recidivism, and post-kala-azar dermal Leishmaniasis (McGwire
and Satoskar, 2014). Around 1.3 million cases of Leishmaniasis
are reported annually worldwide and there is an estimative that
350 million people in 88 countries are living at risk of developing
Leishmaniasis (Kedzierski, 2010; World Health Organization
[WHO], 2015b).
There is a huge number of drug treatment available to each
form of Leishmaniasis. Pentavalent antimony is the agent of
choice for the majority forms of such disease (Baiocco et al.,
2009). Amphotericin B, Paromomycin, Pentamidine also have
been used worldwide (Jaureguiberry et al., 2006; Chattopadhyay
and Jafurulla, 2011; Sundar et al., 2011). However, these
drugs are often harmful to the patient, the treatments need
constant follow up and patients may not be 100% recovered
(McGwire and Satoskar, 2014). Therefore, new strategies to treat
Leishmaniasis is a clear need for millions of patients around the
world.
Anti-leishmanial Peptides
Some APPs were reported as acting against Leishmania
species and have been considered a low harmful alternative,
despite of current drugs used to control Leishmania
infections (Chadbourne et al., 2011). Marr et al. (2012)
listed some leishmanicidal peptides, such as Temporins,
Bombins, Magainins, and Cathelicidins (from amphibians
and mammalians), and discussed their mechanism of
action. Arthropods Leishmanicidal peptides are described
in Table 1.
Hence, among the APPs from insect sources, there is
Spinigerin. It is a cysteine-free peptide constitutively expressed
by termite Pseudacanthotermes spiniger. Its minimal inhibitory
concentration (MIC) in bioassays against ﬁlamentous fungi,
yeast, gram-negative bacteria is <5 μM (Landon et al., 2006).
When assayed against Leishmania donovani, spinigerin was able
to cause apoptosis-like cell death (IC50, 150 μM). Landon et al.
(2006) suggested that such peptide could cause such eﬀects
by inhibiting some Leshimanial trypanothione reductase, thus,
arresting detoxiﬁcation processes against reactive oxygen species
(ROS) produced by the host cells.
Eumenitin is a class of small cationic peptides (15 amino acids)
from the venom of the solitary eumenine Eumenes rubronotatus,
which was isolated and characterized by Konno et al. (2006).
Its activity against Gram-positive and Gram-negative bacteria, as
well as its capacity to stimulate degranulation of mast cells are
known since its discovery. However, eumenitin’s leishimanicidal
activity was reported only in Rangel et al. (2011), when the
peptide was assayed against Leishmania major, displaying anti-
parasitic eﬀects at IC50 of 35 μM.
Decoralin belongs to a class of small and linear cationic
α-helical peptides not stabilized by disulﬁde bonds. It was
isolated for the ﬁrst time in Konno et al. (2007) from the
venom of the solitary eumenine wasp Oreumenes decoratus.
Such class of peptides is known to adopt an amphipathic
α-helical conformation, which was reported as essential for its
biological activity (Powers and Hancock, 2003). Hence, decoralin
showed activity against L. major at micromolar concentrations
(IC50 = 72 μM). But when the C-terminal of the peptide was
amidated, the anti-parasitic activity demonstrated a IC50 sixfold
lower, around 11 μM (Konno et al., 2007). Such enhance in
its activity is speculated to be due a stabilization of α-helical
conformation caused by C-terminal amidation, as well as an
extra electrical charge provided by amidation (Sforça et al.,
2004).
Tachyplesin is a class of anti-microbial and APPs from
horseshoe-crab (Tachypleus tridentatus), described for the ﬁrst
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time in Nakamura et al. (1988). This peptide is 17 amino acids
long and have a beta conformation, been active against Gram-
positive and negative bacteria, as well as against virus and
cancer cells (Shen and Wu, 2014). Bioassays using Leishmania
braziliensis demonstrated that tachyplesin could also inhibit this
parasite’s growth at micromolar levels (12.5 μM; Löfgren et al.,
2008).
Therefore, anti-leishmanicidal peptides from insect sources
encompass a safe alternative to control Leishmania infection,
once they are highly eﬀective, but not as harmful as the current
used drugs. The application of biotechnological tools for the
large-scale production of such peptides are essential to aim this
goal.
MALARIA: NEW APPROACHES FOR THE
CONTROL OF Plasmodium SPECIES
Malaria remains one of the most prevalent and debilitating
parasitic infection across Africa, Asia, and America continents.
According to the World Health Organization (WHO),
approximately 207 million people were diagnosed with
Malaria and 627,000 died worldwide from it during 2012
(Ramasamy, 2014). Four species are the main cause of Malaria:
Plasmodium falciparum, P. vivax, P. malariae, and P. ovale,
transmitted by over 70 species of Anopheles’ mosquitoes.
Among the parasites, P. falciparum is the most severe and
responsible for 90% of all malaria deaths (Grimberg and
Mehlotra, 2011).
Plasmodium’s life cycle is complex, involving multiple
developing stages and locations, both in mosquitos and humans.
Although its complex infectious cycle oﬀers multiple sites
for the development of speciﬁc drugs, ﬁnding a universal
drug against malaria has been a challenging task. The major
problem with the currently available anti-malarial drugs is
the consistent resistance developed by some parasites, well-
reported in literature (Bloland, 2001; White, 2004; Carter and
Hurd, 2010; Torrent et al., 2012). Recently, the emerging
resistance toward the drug artemisinin decreased even more
the chances for a cure of Malaria, once that it used
as ﬁrst-line treatment for uncomplicated cases caused by
P. falciparum, in most endemic countries (Biamonte et al.,
2013).
Therefore, the demand for novel therapeutic agents against
Malaria is urgent, especially using new targets. Nowadays,
the new generation of strategies involves the blockage of
malaria transmission by employing genetically modiﬁed vectors,
mosquito pathogens or symbionts that express anti-parasite
molecules (Carter et al., 2013).
Additionally, APPs from the innate immune system of insect
vectors have been used as sources to control sporogonic stages
of the malaria parasites. There are three sources of APPs that are
active against sporogonic forms of parasites: (1) Endogenous –
peptides that form part of the natural mosquito immune
repertoire; (2) Exogenous – peptides isolated from other species;
and (3) Synthetic – rational design of novel compounds (Carter
and Hurd, 2010).
Anti-malarial Peptides
As there is a bigger number of studies on Malaria, there are also
more peptides presenting activity against Plasmodium species
isolated from diﬀerent arthropods (Table 1), including its insect
host, Anopheles sp. (Gwadz et al., 1989; Vizioli et al., 2001; Kim
et al., 2004; Bell, 2011).
Thus, during Anopheles’s life cycle, malaria mosquito vector
(female anopheline) do not develop symptoms related to any
infection. However, it was demonstrated that the insect produces
three classes of anti-malarial peptides: cecropins, defensins, and
gambicins. Recent reports showed that the three classes of
peptides present activity against mosquito-stage and, in some
cases, blood stage parasites (Bell, 2011). Thus, cecropins A
and B demonstrated activity against ookinetes and oocysts of
P. falciparum, P. berghei, P. knowlesia, and P. cymonolgi (Gwadz
et al., 1989; Kim et al., 2004), while gambicin displayed 54–64%
lethality against P. berghei ookinetes at 10–100 μM (Vizioli et al.,
2001).
The ﬁrst report of APPs was described in Boman et al. (1989).
In this study, they analyzed the growth inhibition of P. falciparum
cells using diﬀerent concentrations of cecropin and melittin
peptides, called CA (l–13) and H (l–13; Boman et al., 1989).
During the same year, Gwadz et al. (1989) demonstrated the
anti-malarial activity of Cecropin B (from giant silk moths) at
a concentration of 0.5 μg/μl (128 μM). The peptide prevented
normal development of oocysts from Plasmodium species in
Anopheles gambiae insects previously infected with the parasite
(Gwadz et al., 1989).
Other important source of anti-malarial peptides was isolated
from scorpion and spiders’ venoms. Among these peptides,
there is scorpine, isolated from the scorpion Pandinus imperator,
whose structure resembles a hybrid between a defensin and a
cecropin. This peptide was responsible for the mortality of 98%
of P. berghei gametocytes at 15 μM and 100% reduction of
P. falciparum parasitemia at 5 μM (Carballar-Lejarazu et al.,
2008).
Meucine-24, a α-helical peptide with an N-terminal
homologous to melittin and meucine-25 have been isolated
from the venom of the scorpion Mesobuthus eupeus and showed
ability to inhibit the development of P. berghei ookinetes at
micromolar concentrations (IC50 10–20 μM; Gao et al., 2010).
Moreover, several insect defensins have displayed anti-
malarial activity. Among them, there are two drosomycins
isolated from the Drosophila melanogaster hemolymph.
Drosomycin1 is able to inhibit the development of P. berghei
ookinetes in 76% at 20 μM, while Drosomycin 2 is able to retard
the development of the same parasite in 29% at 20 μM. (Tian
et al., 2008). Similarly, gomesin, an insect defensin isolated from
the hemocytes of the spider Acanthoscurria gomesiana, inhibited
the in vitro growth of intra-erythrocytic forms of P. falciparum,
causing a dramatic reduction of gametocyte exﬂagelation and
oocyst population in both P. falciparum and P. berghei (Moreira
et al., 2007).
As described here, multiple compounds can be
pharmaceutically attractive to treat Malaria, once that current
available anti-malarial drugs are ineﬃcient against parasites.
Therefore, novel peptides can open new perspectives for the
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FIGURE 1 | Mechanism of action of anti-malarial peptides. (A) Ordered toroidal pore formation. (B) Disoredered toroidal pore formation (Source: Segunpta
et al., 2008 with modifications).
development of new anti-parasitic drugs (Leavy, 2010; Vale et al.,
2014).
Structure and Mode of Action of
Anti-malarial Peptides
The description of several anti-microbial peptides with activity
against pathogenic bacteria, fungi, protozoa and other harmful
organisms are well-described in literature. Those peptides are
isolated from diﬀerent sources, varying from human beings,
to plants, insects, marine animals, and even microorganisms
(Pelegrini et al., 2007; Lacerda et al., 2014; Vale et al., 2014; Kang
et al., 2015). However, few of them show anti-parasitic activity,
especially related to human neglected diseases (Li et al., 2006;
Moreira et al., 2007; Tian et al., 2008; Fieck et al., 2010; Gao
et al., 2010; Rangel et al., 2011; Marr et al., 2012). Among these
diseases, Malaria has the most number of published articles on
the discovery and characterization of anti-plasmodium proteins
and peptides. Considering insect peptides with anti-parasitic
activity, Malaria continues reaching the ﬁrst position in tested
molecules, although there are still very few studies demonstrating
anti-malarial activities of insect peptides for future use as
drugs (Boman et al., 1989; Gwadz et al., 1989; Vizioli et al.,
2001; Kim et al., 2004; Moreira et al., 2007; Carballar-Lejarazu
et al., 2008; Tian et al., 2008; Gao et al., 2010; Vale et al.,
2014).
Recently, anti-malarial peptides from insect sources were
classiﬁed into four groups: (i) α-helical peptides deprived of Cys
residues; (ii) β-pleated peptides containing disulﬁde bridges; (iii)
peptides rich in Pro, Gly, His, Arg, and Trp residues; and (iv)
circular anti-microbial peptides (Vale et al., 2014). Out of these
groups, only the ﬁrst one contains peptides from insect sources
with anti-parasitic activities against Plasmodium species.
Thus, α-helical peptides deprived of Cys residues correspond
to linear cationic small peptides with α-helical structure, whose
positive charges come from the presence of Lys and Arg residues.
Another feature is the existence of at least 50% of their content
composed by hydrophobic amino acid residues (Powers and
Hancock, 2003). Cecropins (from H. cecropia) and Melittins
(from A. mellifera venom) are some examples of α-helical
peptides deprived of Cys residues, due to their α-helical domains
and content of hydrophobic residues in the amino-terminal
site, respectively (Raghuraman and Chattopadhyay, 2007; Tanaka
et al., 2008).
For insect α-helical peptides deprived of Cys residues, the
mode of action consists of poration of the lipid membrane
through a disordered toroidally shape lining of peptides
(Figure 1; Yang et al., 2001; Segunpta et al., 2008). The charged
amino acid residues showed to be essential for electrostatic
interactions with the lipid membrane, resulting in pore formation
(Segunpta et al., 2008).
In general, the mechanism of action of anti-malarial peptides
from insect sources are still poorly studied. However, the
activities of distinct APPs obey many of the rules governing their
ability to disrupt bacterial membranes. The interaction with APPs
to the pathogen’s cell membrane appears to be acutely inﬂuenced
by the respective charges and amphipathies of the reactants. In
fact, a comparison between the peptides’ ability to inhibit the
growth of malaria parasites and that of bacteria demonstrates a
remarkable parallelism in the way that each modiﬁcation aﬀects
both activities (Mor, 2009).
TRANSCRIPTOME: PROSPECTION OF
NOVEL MOLECULES FOR THE
CONTROL OF PARASITIC DISEASES
Transcriptome studies are important to understand the
physiology and mechanism of action of parasitic molecules and
have been one of the alternatives in seeking resolutions to certain
diseases, such as Malaria (Tarun et al., 2008). In this report,
transcriptome and proteome of malaria parasite liver stages
displayed essential knowledge about how the parasite behaves
inside host cells. Moreover, transcriptome studies are also being
used to better understand parasite gene proﬁle during infection,
as demonstrated by Ngwa et al. (2013). The report showed
changes in Plasmodium falciparum transcriptome pattern during
its initial phase, describing that modiﬁcations were observed
even during the ﬁrst half hour after human transmission by the
mosquito (Ngwa et al., 2013). Similarly, Hellgren et al. (2013)
used transcriptome data from birds infected with P. relictum,
which causes avian Malaria, to identify and characterize the
MSP1 gene (SGS1 and GRW4). The analysis of those genes could
led to the generation of a new vaccine for the prevention of avian
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Malaria, also becoming a relevant result for epidemiological
studies (Hellgren et al., 2013).
The evaluation of insect transcriptomes, especially the ones
that are hosts of human parasites, have been published
for some species. Hence, analyses of Musca domestica
transcriptome revealed new insights and genes involved in
the prophenoloxidase system (proPO), a pathway related to
melanization in arthropods. The melanin production occurs
after infection, promoting protection against invasion of
pathogens, such as bacteria (Li et al., 2015). Therefore, the novel
information obtained from transcriptome studies allowed a
better understanding on the mechanism of action and immune
functions of the proPO system inM. domestica.
The ineﬃciency of therapeutic strategies to treat protozoa-
related diseases and the frequent incidence of resistance
developed by parasites led to the search for molecules that
can be used as new pharmaceutical products for the treatment
of parasitic diseases. In the last years, transcriptomes have
been employed as promissory source for the prospection of
active proteins and peptides. The availability of high-throughput
transcriptomic technologies has contributed to considerably
enhance the knowledge to understand host–parasite interactions
and to identify new and eﬀective treatments for parasitic diseases,
especially neglected ones (Cantacessi et al., 2015; Davies et al.,
2015). Furthermore, even transcriptome of phytopathogenic
insects could be an interesting source for future prospections of
proteins and peptides for therapeutic use on the treatment of
Chagas disease, Leishmaniasis, and Malaria (Firmino et al., 2013;
Fonseca et al., 2015).
ANTI-PARASITIC PEPTIDES: FUTURE
REALITY FOR DRUG DEVELOPMENT?
Several researches are published every year on the prospection
and discovery of new molecules from diﬀerent sources with
high potential use as drugs against bacterial, fungi, and parasitic
infections (Lacerda et al., 2014; Breen et al., 2015; Kang et al.,
2015; Tam et al., 2015). Insect peptides with anti-parasitic activity
demonstrate to be an interesting tool on the treatment of
neglected diseases, such as Malaria, Leishmaniasis, and Chagas
disease.
Many reasons explain why neglected diseases are out of reach
from eradication. Hygiene issues, social and economic status of
the population and endemic areas full of viable parasite vectors
are some of them (Alvar et al., 2006; European Alliance Against
Malaria, 2007; Klein et al., 2012). Nevertheless, drug ineﬃciency
and misuse, and serious side eﬀects are the main causes of why
these diseases are still increasing in number and area worldwide.
The mechanism of action of the drugs used nowadays for
the treatment of some neglected diseases are yet not well-
known, facilitating mutations triggering drug resistance by the
parasites. Moreover, the poor eﬃcient response of such drugs,
combined with strong side eﬀects, stimulates the development of
alternatives for a better treatment of neglected diseases (Teixeira
et al., 2014; Vale et al., 2014; Visser et al., 2014). As it is occurring
with anti-bacterial drugs, the misuse of anti-parasitic drugs is
also leading to resistance, increasing preoccupation about a
growing arrival of new cases and ineﬃcacy on the treatment of
recurrent cases (White, 2004; Dondorp et al., 2009; Chakravarty
and Sundar, 2010; Alsford et al., 2012; Whyllie et al., 2015).
Nowadays, anti-parasitic drug candidates containing peptides
are still very few, with most of them at Clinical Trials stage
(Fox, 2013). Nonetheless, the fact that pharmaceutical companies
continue avoiding the application of peptides for the production
of drugs goes beyond oral bioavailability and drug resistance
issues. Peptide degradation by digestive enzymes and interactions
with plasma proteins are some conditions that complicate the
utilization of APPs for production of drugs. Furthermore, the cost
of scaling-up the production of organic compounds is still high,
contributing to expensive drugs into the market (Fox, 2013; Vale
et al., 2014).
However, despite all disadvantages, since the 1990s, the
scenario of drug production is changing. The advances on
biotechnology applied for the development of new processes
for the production of proteins and peptides for therapeutic use
stimulated the formulation of diﬀerent drugs with high speciﬁcity
and activity toward their targets, at lower costs and using
faster production methods (Leavy, 2010). Novel improvements
on biocompatible carriers to extend peptide biocompatibility
also contributed for enhancing target reach of peptide’s site of
action (Costa et al., 2011; Maia et al., 2014). Similarly, use of
nanotechnology and peptide encapsulation using biodegradable
polymers allowed to increase the precision of drug target, as
well as enabled long-acting release forms of peptides in the
organism (Anthony and Freda, 2009; Stark, 2011). Therefore, by
2012, numerous peptide drugs were already approved in the US,
reﬂecting in a market of 13 billion dollars, represented by 1.5%
of total global drugs sales. Other countries also approved and
released peptide drugs over the years, especially the Europeans
Germany and UK, responsible for 63% of peptide therapeutics
in the market, followed by France, Italy, Scandinavia, and Spain
(Kaspar and Reichert, 2013; Vale et al., 2014).
Hence, although pharma companies’ main target were small
molecules (below 500 Da), due to their ease of production and
availability for oral application, small drug candidates showed
low speciﬁcity for their targets, enhancing susceptibility to
metabolic inactivation, which increase side eﬀects, dose-response,
and decrease their bioavailability (Craik et al., 2013). Peptides
with average size of 5 kDa, however, displayed high speciﬁcity
toward their targets, decreasing not only the dose of use, but also
harmful side eﬀects. For example, peptide drugs, such as NVB302,
OP-145, Omiganan and Pexiganan, are now in Clinical Trials
(Phases I, II, and III, respectively), as future eﬀective alternatives
for the treatment of Malaria (Fox, 2013). Therefore, peptide
drugs for the treatment of neglected diseases is a reality for future
years, with high chances of improvement and expanding in terms
of variety and application.
CONCLUSION
As described before in this report, the activity of insect
peptides against the parasites Trypanosoma sp., Leishmania
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sp., and Plasmodium sp. encourages advances in this research
investigation, once there is still a great necessity on developing
new eﬀective drugs for the treatment of Chagas disease,
Leishmaniasis, and Malaria, respectively. Although poorly
explored, insect peptides demonstrate high potential for future
application in therapeutics of infectious diseases, especially
parasitic neglected ones.
Currently, Malaria, together with other infection disease, such
as Tuberculosis and AIDS, receives annually signiﬁcant amounts
of international resources for research on the development of
new strategies for their treatment and prevention. Therefore,
it was recently removed from the “Neglected disease” group.
Nevertheless, there is still no treatment 100% eﬃcient for this
disease, but only methods to prolong the life and decrease the
pain of patients (Olliaro et al., 2012; Uniting to Combat NTDs,
2014).
Similarly, Chagas disease continues to represent the parasitic
illness responsible for the highest number of deaths in Latin
America, surpassingMalaria. Considering that 23% of all infected
patients with T. cruzi are located in Brazil, this country stands
out in the number of published articles about the disease, the
parasite, its host vector and on the discovery of novel tools
to treat Chagas’s disease (more than 1400 publications during
the last 70 years). Out of 55 research institutes working with
Chagas’s disease worldwide, six are locate in Brazil. However, yet,
there are very few eﬀective and low toxic drugs available for its
treatment.
In the absence of appropriate drugs, Leishmaniasis has also
represented a health concern, due to its geographic expansion and
urbanization trend. Moreover, the control of human Leishmania
cannot be done without understanding canine Leishmaniasis,
as pet dogs hosting parasites can easily transmit the disease to
humans (Papadopoulou et al., 2005).
Advances on molecular biotechnology allow the production of
diﬀerent proteins and peptides in their active form using several
heterologous systems. Therefore, scaling up the production of
insect peptides for the development of pharmaceutical drugs to be
used on the treatment of parasitic diseases has become a routine
technique. Similarly, transcriptome analyses can be a relevant
tool on the discovery of novel peptides from insect species with
activity against parasites. Therefore, it is clear that insect peptides
present high potential to become the future drugs for decreasing
the number of infectious diseases, such asMalaria, Leishmaniasis,
and Chagas disease.
It is not expected that biotechnological peptides will take over
chemical molecules on the development of new drugs. However,
peptides are already becoming new options for the treatment of
several diseases, from oncology to infectious ones, as they can
cause synergic eﬀects, enhancing the eﬃcacy of drugs at lower
concentration. Therefore, peptide drugs have reached a place of
interest by pharmaceutical companies, where despite of their cost
of production and biochemical challenges to overcome, peptides
demonstrate to be unique in their mechanism of action and
therapeutic use.
Peptide drugs for neglected diseases, such as Malaria,
Leishmaniasis, and Chagas diseases, are still at early stages
compared to other drugs developed for chronic and non-
infectious diseases (Lax, 2010). But even at a slow pace, studies
and researches on peptide drugs are demonstrating to be a reality
for the treatment of neglected diseases. For the next 10–15 years,
new peptide drugs are expected to be at the market for the
treatment of Malaria and, hopefully, for other neglected diseases
including Chagas and Leishmaniasis.
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